Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416526 | 1.00 | CASP3 (0.47) | CASP3CYP1A2TSHRKMT2AFABP5 | |
| SCHEMBL26127649 | 1.00 | CASP3 (0.47) | CASP3CYP1A2TSHRKMT2AFABP5 | |
| SCHEMBL29696633 | 0.91 | CASP3 (0.49) | CASP3CYP1A2TSHRKMT2AFABP5 | |
| SCHEMBL24633569 | 0.91 | CASP3 (0.49) | CASP3CYP1A2TSHRKMT2AFABP5 | |
| SCHEMBL29697687 | 0.91 | CASP3 (0.49) | CASP3CYP1A2TSHRKMT2AFABP5 | |
| SCHEMBL23879119 | 0.91 | CASP3 (0.49) | CASP3CYP1A2TSHRKMT2AFABP5 | |
| SCHEMBL24579191 | 0.91 | CASP3 (0.49) | CASP3CYP1A2TSHRKMT2AFABP5 | |
| SCHEMBL30896052 | 0.91 | CASP3 (0.49) | CASP3CYP1A2TSHRKMT2AFABP5 | |
| SCHEMBL31129066 | 0.91 | CASP3 (0.43) | CASP3CYP1A2TSHRKMT2AFABP5 | |
| SCHEMBL29696769 | 0.90 | CASP3 (0.41) | CASP3CYP1A2TSHRKMT2AFABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114478701-B | Heptapeptide with anti-tumor activity, and preparation method and application thereof | 广西民族大学 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023195516-A1 | PRODUCTION METHOD FOR PEPTIDE COMPOUND | 中外製薬株式会社 | 2023-10-12 | — | — | WO | disclosed |
| US-20230303619-A1 | DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11732002-B2 | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-22 | — | — | US | disclosed |
| EP-2906246-B1 | VEGF NEUTRALIZING PRODRUGS COMPRISING RANIBIZUMAB FOR THE TREATMENT OF OCULAR CONDITIONS CHARACTERIZED BY OCULAR NEOVASCULARIZATION | ASCENDIS PHARMA OPHTHALMOLOGY DIV A/S (DK) | 2023-07-26 | — | — | EP | disclosed |
| CN-114478701-A | Heptapeptide with anti-tumor activity and preparation method and application thereof | 广西民族大学 | 2022-05-13 | — | — | CN | disclosed |
| CN-113692401-A | Process for producing aromatic amino acid derivative | 中外制药株式会社 | 2021-11-23 | — | — | CN | disclosed |
| CN-104755103-A | VEGF neutralizing prodrugs for the treatment of ocular conditions | ASCENDIS PHARMA OPHTHALMOLOGY DIVISION AS | 2015-07-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11732002-B2 | Deprotection method and resin removal method in solid-phase reaction for peptide compound or amide compound, and method for producing peptide compound | VIP, PEPD, MLN | CASP3 1491/4885CYP1A2 4726/4885TSHR 1382/4885 |
| US-20230303619-A1 | DEPROTECTION METHOD AND RESIN REMOVAL METHOD IN SOLID-PHASE REACTION FOR PEPTIDE COMPOUND OR AMIDE COMPOUND, AND METHOD FOR PRODUCING PEPTIDE COMPOUND | VIP, PEPD, MLN | CASP3 1491/4885CYP1A2 4726/4885TSHR 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.